Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03599453
Title Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.